Sandy Draper
Stock Analyst at Guggenheim
(2.92)
# 1,446
Out of 5,124 analysts
113
Total ratings
59.14%
Success rate
20.63%
Average return
Main Sectors:
Stocks Rated by Sandy Draper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MEDP Medpace Holdings | Maintains: Buy | $464 → $432 | $608.89 | -29.05% | 12 | Jul 24, 2024 | |
| EVH Evolent Health | Maintains: Hold | $34 → $28 | $4.02 | +596.52% | 10 | May 14, 2024 | |
| IQV IQVIA Holdings | Downgrades: Neutral | n/a | $240.53 | - | 8 | Feb 15, 2024 | |
| CRL Charles River Laboratories International | Downgrades: Neutral | n/a | $216.11 | - | 15 | Feb 15, 2024 | |
| GDRX GoodRx Holdings | Maintains: Buy | $8 → $10 | $2.90 | +244.83% | 4 | Aug 10, 2023 | |
| DOCS Doximity | Downgrades: Neutral | n/a | $45.69 | - | 3 | Aug 9, 2023 | |
| TOI The Oncology Institute | Maintains: Buy | $3 → $2 | $4.13 | -51.57% | 3 | Jun 16, 2023 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $271 → $263 | $201.48 | +30.53% | 13 | Apr 28, 2023 | |
| AGL agilon health | Maintains: Buy | $21 → $30 | $0.82 | +3,576.47% | 3 | Mar 6, 2023 | |
| HQY HealthEquity | Maintains: Buy | $89 → $94 | $95.45 | -1.52% | 11 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $8.00 | - | 10 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $51 | $24.43 | +108.76% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $143 → $129 | $248.74 | -48.14% | 2 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $55 | $45.64 | +20.51% | 2 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $226 → $168 | $101.65 | +65.27% | 2 | May 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $12 | $35.46 | -66.16% | 1 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $9.15 | +446.45% | 1 | Jan 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $12.80 | +407.81% | 1 | Jan 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $36 | $2.38 | +1,412.61% | 4 | May 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $167 | $237.87 | -29.79% | 3 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $0.98 | - | 2 | May 31, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $63 | $12.18 | +417.24% | 1 | Sep 20, 2016 |
Medpace Holdings
Jul 24, 2024
Maintains: Buy
Price Target: $464 → $432
Current: $608.89
Upside: -29.05%
Evolent Health
May 14, 2024
Maintains: Hold
Price Target: $34 → $28
Current: $4.02
Upside: +596.52%
IQVIA Holdings
Feb 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $240.53
Upside: -
Charles River Laboratories International
Feb 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $216.11
Upside: -
GoodRx Holdings
Aug 10, 2023
Maintains: Buy
Price Target: $8 → $10
Current: $2.90
Upside: +244.83%
Doximity
Aug 9, 2023
Downgrades: Neutral
Price Target: n/a
Current: $45.69
Upside: -
The Oncology Institute
Jun 16, 2023
Maintains: Buy
Price Target: $3 → $2
Current: $4.13
Upside: -51.57%
ICON Public Limited Company
Apr 28, 2023
Maintains: Buy
Price Target: $271 → $263
Current: $201.48
Upside: +30.53%
agilon health
Mar 6, 2023
Maintains: Buy
Price Target: $21 → $30
Current: $0.82
Upside: +3,576.47%
HealthEquity
Dec 7, 2022
Maintains: Buy
Price Target: $89 → $94
Current: $95.45
Upside: -1.52%
Oct 24, 2022
Upgrades: Neutral
Price Target: n/a
Current: $8.00
Upside: -
Aug 12, 2022
Maintains: Buy
Price Target: $36 → $51
Current: $24.43
Upside: +108.76%
May 25, 2021
Maintains: Buy
Price Target: $143 → $129
Current: $248.74
Upside: -48.14%
May 18, 2021
Maintains: Buy
Price Target: $84 → $55
Current: $45.64
Upside: +20.51%
May 12, 2021
Maintains: Buy
Price Target: $226 → $168
Current: $101.65
Upside: +65.27%
Apr 21, 2021
Initiates: Hold
Price Target: $12
Current: $35.46
Upside: -66.16%
Jan 28, 2021
Initiates: Buy
Price Target: $50
Current: $9.15
Upside: +446.45%
Jan 28, 2021
Initiates: Buy
Price Target: $65
Current: $12.80
Upside: +407.81%
May 13, 2020
Maintains: Buy
Price Target: $30 → $36
Current: $2.38
Upside: +1,412.61%
Mar 26, 2020
Maintains: Buy
Price Target: $175 → $167
Current: $237.87
Upside: -29.79%
May 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $0.98
Upside: -
Sep 20, 2016
Initiates: Buy
Price Target: $63
Current: $12.18
Upside: +417.24%